Study on Roflumilast and Formoterol Interaction
Author Information
Author(s): Christian de Mey, Nassr Nassr, Gezim Lahu
Primary Institution: ACPS - Applied Clinical Pharmacology Services, Mainz-Kastel, Germany
Hypothesis
Does the combination of roflumilast and formoterol lead to any pharmacokinetic or pharmacodynamic interactions in healthy subjects?
Conclusion
The study found no clinically relevant pharmacokinetic or pharmacodynamic interactions between roflumilast and formoterol.
Supporting Evidence
- The study involved 27 healthy male subjects, with 24 being evaluable.
- No severe or serious adverse events were reported during the study.
- Roflumilast was well tolerated with no significant changes in cardiovascular parameters.
- Formoterol was associated with a slight increase in heart rate but did not affect cardiac repolarization.
Takeaway
This study looked at whether two asthma medications, roflumilast and formoterol, work well together without causing problems. They found that using them together is safe.
Methodology
This was a single-centre, open, randomised, multiple-dose, parallel-group study involving healthy male subjects.
Potential Biases
There may be a risk of bias due to the open-label design of the study.
Limitations
The study was conducted only in healthy males aged 18 to 45, which may limit the generalizability of the findings to other populations.
Participant Demographics
Caucasian males aged 18 to 45 years with a body mass index between 18 and 30 kg/m2.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website